HUMANISED ANTIBODIES TO β-AMYLOID PEPTIDE Russian patent published in 2013 - IPC C07K16/18 A61K39/395 C12N15/13 C12N15/63 G01N33/563 A61P25/28 

FIELD: chemistry.

SUBSTANCE: invention discloses an isolated antibody which selectively binds to the C-end of beta-amyloid (Abeta) and is humanised or fully human. The antibody can be a single-chain antibody (scFv), a Fab fragment or a P(ab')₂ fragment. The antibody is capable of preventing oligomerisation of Abeta. The invention discloses a nucleic acid sequence which codes the disclosed antibody, a vector and a host cell for producing the antibody, as well as a pharmacological composition for treating neurological disorders, particularly Alzheimer's disease. The invention provides methods for diagnosis using labelled antibodies disclosed herein and treating neurological disorders associated with abnormal accumulation and/or deposition of Abeta in the central nervous system by administering a therapeutically effective amount of a polynucleotide, vector or host cell to a subject.

EFFECT: invention enables successful application of the disclosed antibodies for therapeutic purposes and clinical application since in contrast to mouse antibodies, said antibodies are low- or nonimmunogenic when used in humans.

25 cl, 23 dwg, 1 tbl, 17 ex